Membrane-targeted DNA frameworks with biodegradability recover cellular function and morphology from frozen cells.

Cell freezing is critical for the long-term preservation of biological materials, but is limited by the cytotoxicity and inefficacy of conventional cryoprotective agents, such as dimethyl sulfoxide (DMSO). Here, we introduce DNA frameworks (DFs) as a nanoengineered programmable class of cryoprotectants designed to address these challenges. The DFs feature a programmable scaffolded structure offering large flexible wireframe contacts, cellular target ability, and biodegradability.

A long-staple design approach towards the scalable production of scaffolded DNA origami.

Scaffolded DNA origami enables the programmable construction of nanoscale structures through the hybridization of a long single-stranded scaffold with hundreds of short staple strands. However, the reliance on numerous synthetic oligonucleotides remains a key barrier to scalable and cost-effective production of DNA nanostructures. In this study, we introduce a long-staple design strategy that extends the length of individual staple strands to 100-200 nucleotides (nt), thereby reducing the total number of strands required while maintaining assembly efficiency and structural fidelity.

The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1 regulation in breast cancer.

Molecular classifications of breast cancer (BRC), such as human epidermal growth factor receptor 2 (HER2), luminal A and luminal B, have been developed to reduce unnecessary treatment by dividing patients with BRC into low‑ and high‑risk progression groups. However, these methods do not cover all of the pathological characteristics of BRC, and investigations into novel prognostic/therapeutic markers are thus continually required. In this study, we identified the overexpression of the histone methyltransferase, euchromatic histone‑lysine N‑methyltransferase 2 (EHMT2) in BRC samples (n=1,222) and normal samples (n=113) derived from the TCGA portal by performing a BRC tissue microarray.